Drugs / KL7016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02092207 | Oct 2012 → Jun 2014 | dry eye syndrome | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KL7016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02092207 ↗ |
| Route | Oral | “oral administration” NCT02092207 ↗ |